{
}
Bio-Manguinhos in Brazil is poised to supply its mRNA COVID-19 vaccine, while Kenya's Biovax faces salary competition from commercial firms despite a $120 million World Bank loan. The WHO's mRNA technology transfer program aims to establish sustainable vaccine production in low and middle-income countries, with 11 facilities expected by 2030. However, financial challenges persist, requiring an estimated $200 million to enhance manufacturing capabilities and support ongoing research.
Biovax
Companies
The information provided herein is generated by experimental artificial intelligence and is for informational purposes only.
ustainable mRNA vaccine production initiative aims to enhance global health equity
Institut Pasteur Dakar
International Vaccine Institute
Biovax
Biovac
Moderna, Inc.
BioGeneric
Bio-Manguinhos
Hilleman laboratories
Afrigen
BioFarma
DEU
VNM
BRA
IDN
EGY
SGP
SEN
KOR
CAN
UKR
NOR
FRA
KEN
BEL
ZAF
Charles Goren
Patricia Neves
Indra Rudiansyah
Martin Friede
Drew Weissman
Heba Wali
Petro Terblanche
Show more
18:57 20.11.2024
Trending
Subcategory
Corporate News
Startups & Entrepreneurship
Economic Indicators
Global Trade Developments
Market Analysis and Predictions
Countries:
Companies:
Currencies:
People: